EPHA2 and cancer: Given the involvement of Eph receptors and EphA2 in particular in other highly prevalent diseases including several cancers, more targeted therapeutics aimed at blocking binding to and inhibiting activation of EphA2 in a highly specific manner are being developed[63–65].